New Drugs in JDM Virtual Symposium
October 17, 2020
Learning Objectives
- Appreciate the importance of new drug development in juvenile dermatomyositis
- Understand developments in knowledge of disease pathogenesis that impacts drug development
- Describe the roles of the three medications presented in the treatment of juvenile dermatomyositis
- Increase participation in available clinical trials relevant in treatment of juvenile dermatomyositis
Duke University Health System-Virtual
Durham, NC
27710
United States
Available Credit
- 2.50 AMA PRA Category 1 Credit(s)™
- 2.50 ANCC
- 2.50 Attendance
- 2.50 JA Credit - AH
- 2.50 Approved for AMA PRA Category 1 Credit(s)™